Browse > Article
http://dx.doi.org/10.4333/KPS.2006.36.2.143

Bioequivalence of Procare Tablet to Proscar® Tablet (Finasteride 5 mg)  

Kang, Hyun-Ah (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University, Clinical Trial Center, Chonnam National University Hospital)
Cho, Hea-Young (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University, Clinical Trial Center, Chonnam National University Hospital)
Lee, Yong-Bok (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University, Clinical Trial Center, Chonnam National University Hospital)
Publication Information
Journal of Pharmaceutical Investigation / v.36, no.2, 2006 , pp. 143-148 More about this Journal
Abstract
Finasteride $[N-(1, 1-dimethylethyl)-3-oxo-4-aza-5{\alpha}-androst-1-ene-17{\beta}-carboxamide]$ is a 4-aza-3-oxosteroidal inhibitor of human $5{\alpha}-reductase$. The purpose of the present study was to evaluate the bioequivalence of two finasteride tablets, $Proscar^{\circledR}$ (MSD Korea Ltd.) and Procare (Hana Pharm. Co., Ltd.), according to the guidelines of the Korea Food and Drug Administration (KFDA). The release of finasteride from the two finasteride formulations in vitro was tested using KP VIII Apparatus II method with various dissolution media (pH 1.2, 4.0, 6.8 buffer solution and water). Twenty six healthy male subjects, $23.7\;{\pm}\;2.24$ years in age and $67.2\;{\pm}\;8.55\;kg$ in body weight, were divided into two groups and a randomized $2\;{\time}\;2$ cross-over study was employed. After two tablets containing 5 mg as finasteride was orally administered, blood samples were taken at predetermined time intervals and the concentrations of finasteride in serum were determined using HPLC with UV detector. The dissolution profiles of two formulations were similar in all tested dissolution media. The pharmacokinetic parameters such as $AUC_t,\;C_{max},\;and\;T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t,\;C_{max}$ and untransformed $T_{max}$. The results showed that the differences between two formulations based on the reference drug, $Proscar^{\circledR}$, were 6.39, 4.65 and -13.9% for $AUC_t,\;C_{max},\;and\;T_{max},$ respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log 0.800 to log 1.25 $(e.g.,\;log\;0.990{\sim}log\;1.14\;and\;log\;0.977{\sim}log\;1.13 for\;AUC_t\;and\;C_{max},\;respectively)$. Thus, the criteria of the KFDA bioequivalence guideline were satisfied, indicating Procare tablet was bioequivalent to $Proscar^{\circledR}$ tablet.
Keywords
Finasteride; Proscar; Procare; Bioequivalence; HPLC;
Citations & Related Records
연도 인용수 순위
  • Reference
1 A.L. Dallob, N.S. Sadick, W. Unger, S. Lipert, L.A. Geissler, S.L. Gregoire, H.H. Nguyen, E.C. Moore, W.K. Tanaka, The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness, J. Clin. Endocrinol. Metab., 79(3), 703-706 (1994)   DOI
2 M.L. Constanzer, B.K. Matuszewski, W.F. Bayne, High-performance liquid chromatographic method for the determination of finasteride in human plasma at therapeutic doses, J. Chromatogr., 566(1), 127-134 (1991)   DOI   ScienceOn
3 Statistical Solutions Ltd., Equiv $Test^{circled R}$ 2.0, U.K. (2001)
4 G.H. Rasmusson, G.F. Reynolds, N.G Steinberg, E. Walton, G.F. Patel, T. Liang, M.A. Cascieri, A.H. Cheung, J.R. Brooks, C. Berman, Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding, J. Med. Chem., 29(11), 2298-2315 (1986)   DOI
5 M. Ohtawa, H. Morikawa, J. Shimazaki, Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5$\alpha$-androst-1-ene-17$\beta$-carboxamide, a new type of specific competitive inhibitor of testosterone 5a-reductase, in volunteers, Eur. J. Drug Metab. Pharmacokinet., 16(1), 15-21 (1991)   DOI
6 식품의약품안전청 고시 제 2002-60호, 생물학적동등성시험기준 (2002. 11. 22)
7 식품의약품안전청 고시 제 1999-67호, 의약품임상시험관리기준 (2000. 1. 4)
8 P. Ptacek, J. Macek, J. Klima, Determination of finasteride in human plasma by liquid-liquid extraction and high-performance liquid chromatography, J. Chromatogr. B, 738, 305-310(2000)   DOI   ScienceOn